Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management
Go online to PeerView.com/YVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Across B-cell non-Hodgkin lymphoma settings, the use of targeted agents has in many instances eclipsed the use of standard chemoimmunotherapy. In more aggressive B-cell lymphomas, including in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), progress with targeted therapy has been slower. However, new evidence with BTK inhibitors in MCL and DLBCL indicates that they may boost efficacy when added to proven therapeutic platforms or when used in disease subtypes defined by molecular (eg, activated B-cell) features. At PeerView’s recent “Clinical Consults” event, experts explored the implications of these new developments—highlighting evidence supporting novel BTKi-based combinations, BTKi regimens in diverse DLBCL patient populations, and the important safety considerations necessary for successful use of targeted agents in MCL and DLBCL. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of targeted agent classes in aggressive lymphoma, including BTK, BCL-2, and XPO1 inhibitors as monotherapy or as part of novel combinatorial strategies across MCL and DLBCL treatment settings; Integrate personalized therapeutic platforms with targeted components into the management of patients with MCL or DLBCL, including as first-, second-, or third-line care; and Manage the unique suite of adverse events associated with the single-agent and combination use of targeted agent classes in the setting of aggressive lymphoma